Artigo de peri??dico
Application of OSL dosimetry and 3D printed phantom for comparison of calculation algorithms for VMAT treatment planning
Registro en:
2674-9688
1
1
10.34019/2674-9688.2019.v1.28227
0000-0001-7137-0613
Sem Percentil
Sem Percentil CiteScore
Autor
VILLANI, DANIEL
MORENO, CAROLINA dos S.
SAKURABA, ROBERTO K.
CAMPOS, LETICIA L.
Resumen
The application of new commercial and industrial technologies in the fields of dosimetry and
medical physics is of great interest to the scientific community, both to validate existing
protocols and to develop new methodologies. The popularization of 3D printing techniques
has been analyzed as a great advantage in quality control in complex treatment techniques,
such as radiotherapy and the development of patient simulators. Portable dosimetry systems
such as Landauer MicroStar OSL system are versatile and their use in quality control is of
great importance. The aim of this paper is to compare two of the most used dose calculation
algorithms used in Varian Eclipse TPS ??? AAA and Acuros XB ??? for treatment planning of
multiple brain metastases using a 3D printed anthropomorphic phantom and the OSL InLight
system for experimental dosimetry validation. A 3D printed anthropomorphic skull phantom
was submitted to a CT scan and planed five target volumes. In order of comparison, two
dose calculations were performed in the Varian Eclipse 13.6 TPS with "Alabama technique",
using the Varian???s AAA and AXB algorithms, and treatment delivered with 6 MV photon beam
of a Varian TrueBeam linear accelerator. Landauer nanoDot dosimeters were positioned
inside each of the five target volumes planned and the experimental dosimetric results were
compared with the algorithms??? calculated doses. The findings of this work indicate that
ACUROS XB calculates more accurate doses compared with AAA, with all the experimental
agreements better than 96.0 %, probably because of the heterogeneity corrections. The
uncertainty analysis of the InLight system device is enough to sustain the dosimetric
uncertainties below 3.0 %, validating the results.